These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23127761)

  • 1. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
    Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
    Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
    Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
    Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
    Fernandes MS; Reddy MM; Croteau NJ; Walz C; Weisbach H; Podar K; Band H; Carroll M; Reiter A; Larson RA; Salgia R; Griffin JD; Sattler M
    J Biol Chem; 2010 Oct; 285(42):32596-605. PubMed ID: 20622007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
    Taylor SJ; Thien CB; Dagger SA; Duyvestyn JM; Grove CS; Lee BH; Gilliland DG; Langdon WY
    Exp Hematol; 2015 Mar; 43(3):191-206.e1. PubMed ID: 25534201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
    Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
    Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flt3-dependent transformation by inactivating c-Cbl mutations in AML.
    Sargin B; Choudhary C; Crosetto N; Schmidt MHH; Grundler R; Rensinghoff M; Thiessen C; Tickenbrock L; Schwäble J; Brandts C; August B; Koschmieder S; Bandi SR; Duyster J; Berdel WE; Müller-Tidow C; Dikic I; Serve H
    Blood; 2007 Aug; 110(3):1004-12. PubMed ID: 17446348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
    Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Döhner H; Döhner K; Schittenhelm MM
    Mol Cancer; 2013 Mar; 12():19. PubMed ID: 23497317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
    Zeng Z; Samudio IJ; Zhang W; Estrov Z; Pelicano H; Harris D; Frolova O; Hail N; Chen W; Kornblau SM; Huang P; Lu Y; Mills GB; Andreeff M; Konopleva M
    Cancer Res; 2006 Apr; 66(7):3737-46. PubMed ID: 16585200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cbl participates in shikonin-induced apoptosis by negatively regulating phosphoinositide 3-kinase/protein kinase B signaling.
    Qu D; Xu XM; Zhang M; Jiang TS; Zhang Y; Li SQ
    Mol Med Rep; 2015 Jul; 12(1):1305-13. PubMed ID: 25815461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.
    Rathinam C; Thien CB; Flavell RA; Langdon WY
    Cancer Cell; 2010 Oct; 18(4):341-52. PubMed ID: 20951944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors.
    Makishima H; Sugimoto Y; Szpurka H; Clemente MJ; Ng KP; Muramatsu H; O'Keefe C; Saunthararajah Y; Maciejewski JP
    Leukemia; 2012 Jul; 26(7):1547-54. PubMed ID: 22246246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
    Belizaire R; Koochaki SHJ; Udeshi ND; Vedder A; Sun L; Svinkina T; Hartigan C; McConkey M; Kovalcik V; Bizuayehu A; Stanclift C; Schenone M; Carr SA; Padron E; Ebert BL
    Blood; 2021 Apr; 137(16):2209-2220. PubMed ID: 33512474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor.
    Tse KF; Novelli E; Civin CI; Bohmer FD; Small D
    Leukemia; 2001 Jul; 15(7):1001-10. PubMed ID: 11455967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling.
    Kazi JU; Rupar K; Marhäll A; Moharram SA; Khanum F; Shah K; Gazi M; Nagaraj SR; Sun J; Chougule RA; Rönnstrand L
    Oncotarget; 2017 Feb; 8(7):12194-12202. PubMed ID: 28086240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Cbl promotes T cell receptor-induced thymocyte apoptosis by activating the phosphatidylinositol 3-kinase/Akt pathway.
    Thien CB; Dagger SA; Steer JH; Koentgen F; Jansen ES; Scott CL; Langdon WY
    J Biol Chem; 2010 Apr; 285(14):10969-81. PubMed ID: 20133944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
    Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Toure AA; Buhrlage S; Liu X; Wang J; Gray N; Stone R; Adamia S; Winer E; Sattler M; Griffin JD
    J Cell Mol Med; 2020 Feb; 24(3):2145-2156. PubMed ID: 31943762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT; Levis M; Small D
    Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
    Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
    Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
    Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.